Mabwell Therapeutics, Inc. Sustainability Profile
Mabwell Therapeutics, Inc., a leading biopharmaceutical company headquartered in the United States, is at the forefront of innovative therapeutic solutions. Founded in 2016, Mabwell focuses on the research, development, and commercialisation of monoclonal antibodies and other biologics, primarily targeting oncology and autoimmune diseases. With a strong presence in both the US and China, Mabwell has achieved significant milestones, including the successful development of unique antibody therapies that address unmet medical needs. Their core products stand out due to their advanced engineering and specificity, positioning the company as a notable player in the global biopharmaceutical landscape. Mabwell's commitment to scientific excellence and patient-centric solutions underscores its reputation as a trusted name in the industry.
DitchCarbon Score
How does Mabwell Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mabwell Therapeutics, Inc.'s score of 5 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mabwell Therapeutics, Inc.'s reported carbon emissions
Mabwell Therapeutics, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Mabwell (Shanghai) Bioscience Co., Ltd., which may influence its climate commitments and reporting practices. As of now, there are no documented reduction targets or climate pledges from Mabwell Therapeutics, Inc. This absence of data suggests that the company may still be in the early stages of establishing its carbon footprint and climate strategy. Given the lack of specific emissions figures, it is essential for Mabwell Therapeutics to develop and communicate clear sustainability goals and initiatives to align with industry standards and expectations. This could include setting science-based targets for emissions reductions and participating in recognised climate initiatives to enhance its environmental accountability.
How Carbon Intensive is Mabwell Therapeutics, Inc.'s Industry?
How Carbon Intensive is Mabwell Therapeutics, Inc.'s Location?
Mabwell Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Mabwell Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
